Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Indonesia to ink Pfizer, AstraZeneca vaccine deals as awaits Sinovac clearance

Tue, 29th Dec 2020 11:38

(Recasts, adds vox pops on vaccine hesitancy)

By Stanley Widianto and Yuddy Cahya Budiman

JAKARTA, Dec 29 (Reuters) - Indonesia is poised to secure
coronavirus vaccines from Pfizer and AstraZeneca, the health
minister said on Tuesday, as it awaits authorisation to begin
its inoculation programme with a third drug, by China's Sinovac.

Budi Gunadi Sadikin said a 50-million-dose deal with
AstraZeneca would be finalised before the end of the
year, and one of the same size with Pfizer in the first
week of January.

The first shots for both those drugs, which have gained
regulatory approval in many western countries, are not scheduled
to arrive for months, the minister told his first news
conference.

So Indonesia plans to start vaccinations with the Sinovac
treatment, of which it secured 1.2 million doses this
month and expects 1.8 million more in January, once it gains
emergency use clearance.

Interim results from its phase III trial are expected to be
delivered to Indonesia's Food and Drug Agency next month.

Budi said the country's 1.3 million front-line health
workers would get priority in the first wave of vaccinations
between January and April. "They are the most important group of
people in our battle against the pandemic," he told a news
conference.

The world's fourth most populous country has had over
727,000 confirmed COVID cases and 21,700 deaths, among Asia's
highest tallies.

Public servants will be next in line for shots, with those
in infection "red-zones" aged between 18 and 59 prioritised in a
second round of vaccinations.

Indonesia is focusing its programme on that age range rather
than the elderly in an effort to safeguard the working
population.

Bambang Heriyanto, corporate secretary of state-owned
drugmaker Bio Farma, said that strategy would allow Indonesia to
reach herd immunity.

Including Tuesday's announcement, Indonesia has secured 329
million vaccine doses, including about 125 million from Sinovac,
50 million from Novavax and 54 million from global vaccine
programme COVAX.

The AstraZeneca vaccines are expected to arrive in the
second quarter of 2021 and Pfizer's in the third quarter,
according to a slide presentation by Budi.

The companies were not immediately available for comment.

IS IT SAFE? IS IT HALAL?

The vaccine deals met with mixed reactions on the streets of
the capital Jakarta on Tuesday.

"There's lots of diseases with no cure, but there's already
(a) cure for COVID," said 25-year-old radio announcer Cindy
Lauw, "I'm just wary."

Suhaimi, a 55-year-old retiree, said he would await trial
results, and news about whether the vaccine was permitted under
Islam.

A December survey by Indonesian pollster Saiful Mujani
Research and Consulting showed 37% of 1,202 respondents were
willing to be vaccinated, while 40% would consider it and 17%
would refuse.

While acknowledging the essential role of vaccinations,
epidemiologist Pandu Riono warned against over-reliance on them.

"Vaccines are the second step in prevention, the first is
behaviour and surveillance, testing, contact tracing and
isolation," he said.
(Additional reporting by Angie Teo;
Writing by Kate Lamb;
Editing by Martin Petty, Robert Birsel and John Stonestreet)

More News
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.